Abstract Background Hepatocellular carcinoma (HCC) is often caused by chronic liver infection or inflammation. Searching for potential immunotherapy targets will aid the early diagnosis and treatment of HCC. Methods Firstly, detailed HCC data were downloaded from The Cancer Genome Atlas database. GDCRNATools was used for the comprehensive analysis of RNA sequencing data. Subsequently, the CIBERSORT package was used to estimate infiltration scores of 22 types of immune cells in complex samples. Furthermore, hub genes were identified via weighted gene co-expression network analysis (WGCNA) and protein-protein interaction (PPI) network analysis. In addition, multiple databases were used to validate the expression of hub gene in the tumor tissu...
The aim of the current study was to identify biomarkers that correlate with the Barcelona Clinic Liv...
Immunity plays an important role in tumor development. In this study, we aimed to investigate molecu...
Aim: Existing targeted therapies for hepatocellular carcinoma (HCC) are resistant and have limitatio...
Background: Immune checkpoint inhibitor (ICI) therapy has been proved to be a promising therapy to m...
Hepatocellular carcinoma is a common malignant tumor with poor prognosis, poor treatment effect, and...
Background: The prognosis of patients with hepatocellular carcinoma (HCC) is negatively affected by ...
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death. HBV infection i...
Aim: Existing targeted therapies for hepatocellular carcinoma (HCC) are resistant and have limitatio...
Hepatocellular carcinoma (HCC) ranks fifth among common cancers and is the second most common cause ...
Hepatocellular carcinoma (HCC), a highly aggressive tumor, has high incidence and mortality rates. R...
Abstract Background Hepatocellular carcinoma (HCC) is an aggressive cancer with a high rate of death...
Background: Tumor growth depends on tumor cells and the tumor microenvironment, which are regulated ...
The aim of the current study was to identify biomarkers that correlate with the Barcelona Clinic Liv...
Abstract Background Hepatocellular carcinoma (HCC) is a disease with a high incidence and a poor pro...
BackgroundThe incidence of hepatocellular carcinoma (HCC) is rising worldwide, and there is limited ...
The aim of the current study was to identify biomarkers that correlate with the Barcelona Clinic Liv...
Immunity plays an important role in tumor development. In this study, we aimed to investigate molecu...
Aim: Existing targeted therapies for hepatocellular carcinoma (HCC) are resistant and have limitatio...
Background: Immune checkpoint inhibitor (ICI) therapy has been proved to be a promising therapy to m...
Hepatocellular carcinoma is a common malignant tumor with poor prognosis, poor treatment effect, and...
Background: The prognosis of patients with hepatocellular carcinoma (HCC) is negatively affected by ...
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death. HBV infection i...
Aim: Existing targeted therapies for hepatocellular carcinoma (HCC) are resistant and have limitatio...
Hepatocellular carcinoma (HCC) ranks fifth among common cancers and is the second most common cause ...
Hepatocellular carcinoma (HCC), a highly aggressive tumor, has high incidence and mortality rates. R...
Abstract Background Hepatocellular carcinoma (HCC) is an aggressive cancer with a high rate of death...
Background: Tumor growth depends on tumor cells and the tumor microenvironment, which are regulated ...
The aim of the current study was to identify biomarkers that correlate with the Barcelona Clinic Liv...
Abstract Background Hepatocellular carcinoma (HCC) is a disease with a high incidence and a poor pro...
BackgroundThe incidence of hepatocellular carcinoma (HCC) is rising worldwide, and there is limited ...
The aim of the current study was to identify biomarkers that correlate with the Barcelona Clinic Liv...
Immunity plays an important role in tumor development. In this study, we aimed to investigate molecu...
Aim: Existing targeted therapies for hepatocellular carcinoma (HCC) are resistant and have limitatio...